Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05890911 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 1 to 3v6
  2. Primary completion pushed from May 2026 to Dec 2026v5
  3. Primary completion date: Nov 2025 to May 2026
    • Study completion date: Dec 2025 to Dec 2026
    v4
  4. Primary completion date: Dec 2024 to Nov 2025v3
  5. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Dec 2024 to Dec 2025
    • Start date changed from estimate of Jun 2023 to Jun 1, 2023
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The participants in the study will be adult patients with suspected sleep-disordered breathing. A one-night polysomnography will be performed using the NOXA1 device (NOX Medical, Reykjavík, Iceland). During the polysomnographic examination, sleep, breathing, heart rate and activity of the masticatory muscles will be recorded. Blood sample will be taken from each of the participants qualified to the study and control group to determine the level of dopamine and used to perform genetic tests of selected single nucleotide polymorphisms occurring within the genes regulating the concentration of dopamine and genes encoding dopamine receptors.
Trial Details
NCT Number NCT05890911
Lead Sponsor Wroclaw Medical University
Conditions
(from sponsor)		 Sleep Apnea, Sleep-Disordered Breathing
Related terms Sleep Apnea Syndromes, Sleep Wake Disorders
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov